Prescription for change: diversity’s missing link in Canada’s health-care system

If Canada were to deploy pharmacogenetic-guided treatments for patients with depression, we would save on average $3,000 per patient. If only 50 per cent of the 1.6 million Canadians with depression were treated based on this method, we would save $2.4-billion per year.

Several studies have shown that personalizing patient treatments based on their unique genotype can improve treatment outcomes, minimize adverse drug effects, and save health-care costs, writes Chukwunonso Nwabufo. Image courtesy of Pexels/Pixabay

Opinion

BY CHUKWUNONSO NWABUFO

March 7, 2024

We must evaluate the current and future state of personalized medicine in this era of diversity and inclusion. Canada spends approximately $13-billion annually on adverse drug effects partly because health-care providers are not we...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy